US Medical Affairs Lead, Oncology - Lung

GSK•Philadelphia, PA

1d•Hybrid

About The Position

At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. The US Medical Affairs Lead (MAL), Lung is the single point of medical accountability for assigned lung oncology pipeline assets and/or indications in the US. The role leads development and execution of Medical Plans, integrating headquarters medical strategy with field medical execution to ensure robust bidirectional insight generation, support clinical trial site selection and enrollment, and build medical and evidence foundations required for successful transition of assets for commercialization.

Requirements

Advanced scientific or clinical degree such as MD, PharmD, PhD, or equivalent.
Eight or more years of Oncology experience in Medical Affairs, including US launch or launch preparation experience.
Three or more years of experience shaping clinical trial design to fit US Market needs.
Five or more years of experience developing medical strategy and evidence generation plans, and to deliver against asset operational plans.

Nice To Haves

Experience supporting oncology pipeline or early‑asset programs.
Experience influencing clinical development strategy through medical insight.
Strong understanding of US oncology practice patterns and clinical trial execution.
Demonstrated ability to work effectively in a complex, matrixed environment.

Responsibilities

Accountable for development and execution of US medical strategy for lung oncology pipeline assets, ensuring alignment with asset strategy and Emerging Therapeutic Area priorities.
Leads the US Medical Affairs Plan and Medical Matrix Team, adapting global strategy to US clinical practice, research infrastructure, and stakeholder needs.
Represents the US medical perspective on Global Medical Teams, providing a strong US voice on unmet need, trial feasibility, and external expert expectations.
Partners closely with Clinical Development to inform protocol design, eligibility criteria, endpoints, and site selection to optimize US relevance and enrollment.
Drives systematic generation, synthesis, and communication of US medical insights from investigators, HCPs, and research networks.
Provides strategic direction to Lung MSLs on engagement priorities, insight focus areas, and ISS/SCS concepts aligned to US medical strategy.
Works with Value Evidence & Outcomes partners to identify US evidence gaps and shape local evidence generation plans.
Ensures high‑quality, compliant medical engagement with external lung oncology experts and cooperative groups.
Manages budget and spend for assigned lung oncology assets in accordance with governance requirements.
Applies sound medical governance and is accountable for medical review, approval, and compliance oversight for assigned assets.